Substandard and falsified anti-tuberculosis drugs: A preliminary field analysis

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 3, 2013, Pages 308-311

  Bate, R ^a   Jensen, P ^b   Hess, K ^c   Mooney, L ^d   Milligan, J ^a  

^a AMERICAN ENTERPRISE INSTITUTE   (United States)

^b Pivit LLC HQ   (United States)

^c Africa Fighting Malaria   (United States)

^d Africa Fighting Malaria   (United Kingdom)

Author keywords

Drug resistance; Malaria; MDR TB; Substandard drugs; XDR TB

Indexed keywords

ISONIAZID; RIFAMPICIN;

ARTICLE; DRUG CONTROL; DRUG MONITORING; DRUG QUALITY; DRUG RESISTANCE; INCOME; PRIORITY JOURNAL; QUALITY CONTROL; TABLET DISINTEGRATION; THIN LAYER CHROMATOGRAPHY;

AFRICA; ANTITUBERCULAR AGENTS; ASIA; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, THIN LAYER; COMMUNITY PHARMACY SERVICES; COUNTERFEIT DRUGS; CRIME; DEVELOPING COUNTRIES; DRUG RESISTANCE, BACTERIAL; DRUG STABILITY; DRUG STORAGE; HUMANS; ISONIAZID; PRIVATE SECTOR; QUALITY CONTROL; RIFAMPIN; RUSSIA; SOLUBILITY;

EID: 84874069619     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0355     Document Type: Article

References (26)

1. World Health Organization. Global tuberculosis control: WHO report 2011. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 2011.
2. Munro S A, Lewin S A, Smith H J, Engel M E, Fretheim A, Volmink J. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med 2007; 4: e238.
3. World Health Organization. Treatment of tuberculosis: guidelines. 4th ed. WHO/HTM/TB/2009.420. Geneva, Switzerland, 2010.
4. Caminero J A. Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis 2010; 14: 382-390.
5. Chiang C-Y, Schaaf H S. Management of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2010; 14: 672-682.
6. Gandhi N, Moll A, Sturm A W, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
7. Kelesidis T, Kelesidis I, Refailidis P I, Falagas M E. Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. J Antimicrob Chemother 2007; 60: 214-236.
8. Bate R, Coticelli P, Tren R, Attaran A. Antimalarial drug quality in the most severely antimalarial parts of Africa - a six country study. PLoS ONE 2008; 3: e2132.
9. Singh S, Bhutani H, Mariappan T T. Quality problems of anti-tuberculosis fixed-dosed combinations (FDCs): a way forward. Indian J Tuberc 2006; 53: 201-205.
10. Laserson K F, Kenyon A S, Kenyon T A, Layloff T, Binkin N J. Substandard tuberculosis drugs on the global market and their simple detection. Int J Tuberc Lung Dis 2001; 5: 448-454.
11. Ellard G A. The colorimetric analysis of anti-tuberculosis fixed-dose combination tablets and capsules. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S343-S346.
12. Ashokraj Y, Agrawal S, Varma M V S, et al. Quality control of anti-tuberculosis fixed-dose combination formulations in the global market: an in vitro study. Int J Tuberc Lung Dis 2004; 8: 1081-1088.
13. Bate R, Tren R, Mooney L, et al. Pilot study of essential drug quality in two major cities in India. PLoS ONE 2009; 4: e6003.
14. World Health Organization. WHO model list of essential medicines - 17th list. Geneva, Switzerland, 2011. http://whqlibdoc.who.int/hq/2011/a95053-eng.pdf Accessed November 2012.
15. Bate R, Hess K. Anti-malarial drug quality in Lagos and Accra - a comparison of various quality assessments. Malar J 2010; 9: 157.
16. Bate R, Mooney L, Hess K. Medicine registration and medicine quality: a preliminary analysis of key cities in emerging markets. Res Rep Trop Med 2010; 1: 89-93.
17. Kenyon A S, Flinn P E, Layloff T P. Rapid screening of pharmaceuticals by thin layer chromatography: analysis of essential drugs by visual methods. J AOAC Int 1995; 78: 41-49.
18. Clift C. Chatham House meeting summary: counterfeit, falsified and substandard medicines 2010. London, UK: Chatham House, 2010. http://www.chathamhouse.org/sites/default/files/public/Research/Global%20Health/ 161210summary.pdf Accessed November 2012.
19. Agrawal S, Panchagnula R. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations. Int J Pharm 2004; 287: 97-112.
20. Wells W A, Ge C F, Patel N, Oh T, Gardiner E, Kimerling M E. Size and usage patterns of private TB drug markets in the high burden countries. PLoS ONE 2011; 6: e18964.
21. Seear M, Gandhi D, Carr R, Dayal A, Raghavan D, Sharma N. The need for better data about counterfeit drugs in developing countries: a proposed standard research methodology tested in Chennai, India. J Clin Pharm Ther 2011; 36; 4: 488-495.
22. Bate R. Phake: the deadly world of falsified and substandard medicines. Washington DC, USA: AEI Press, 2012.
23. Newton C R, Krishna S. Severe falciparum malaria in children: current understanding of pathophysiology and supportive treatment. Pharmacol Ther 1998; 79: 1-53.
24. Udwadia Z F, Amale R A, Ajbani K K, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012; 54: 579-581.
25. Resch S C, Salomon J A, Murray M, Weinstein M C. Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med 2006; 3: e241.
26. O'Brien R, Nunn P. The need for new drugs against tuberculosis. Am J Respir Crit Care Med 2001; 162: 1055-1058.